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Numerous studies have implicated various roles in carcinogenesis for dominant-
acting oncogenes, activated by mutation, chromosomal rearrangement, insertion
ofanearby promoterelement, or gene amplification [1-5]. Other studies have indi-
cated that tumorigenicity behaves as a recessive trait, in that dominant elements
(suppressor genes) must first be inactivated (e.g., by gene or chromosomal deletion,
rearrangementormutation) in orderfor acell to become neoplastic (6-8). Presum-
ably, normal progenitor cellswould require aspecific series ofgene activations and/or
inactivations to complete the transformation process. Moreover, depending upon
the tumor typeand the differentiation program ofthe cell, it islikely that this series
ofchanges would differ. The determination ofa contributing role for oncogenes in
the sequence ofsteps required for malignant transformation would require, there-
fore, an ability todirectly test theeffectsofoncogeneson normal differentiated diploid
progenitor cells ofa particular tumortype (9). Human renal cellsprovide asuitable
system for examining the temporal sequence ofoncogene-related effects for several
reasons. First, cells from both renal cancers and normal human kidney can be cul-
tured, thereby enabling a direct comparison of the normal and malignant pheno-
types(10-13). Second, immunofluorescent stainingwith mAbs generated againstgly-
coproteins, glycolipids, and blood group antigens of normal and malignant renal
cells demonstrate that -90% of cultured normal human kidney cells and virtually
all renal cell carcinomas (as distinguished from transitional cell carcinomas of the
kidney) are ofproximal tubule derivation (10, 14-20). Thus, transformation experi-
ments with normal proximal tubule (PT)' cells would presumably directly relate
to events occurring in vivo. Third, specific quantitative and qualitative changes in
proximal tubular antigens that occur upon neoplastic transformation ofthe PT cell
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in vivo are well documented (16, 20-22). Therefore, the contributing role of on-
cogenes in the phenotypic alterations associated with transformation can be dissected.
Ki-ras and Ha-ras oncogenes encode related 21,000 dalton proteins that have trans-
forming potential (23) . We have previously shown that viral ras oncogenes induce
in normal human melanocytes a wide range of transformation-related phenotypic
traits characteristic of melanoma cells (24, 25). In this report, we have examined
the biologic, antigenic and genetic effects of introducing either the viral Ki-ras or
the viral Ha-ras oncogenes into primary cultures of normal human renal PT cells.
Materials and Methods
Tissue Culture.
￿
PT cell cultures and renal carcinoma cell lines (denoted as SK-RC) were
derived as described previously (10). Cultures were maintained in Eagle's MEM supplemented
with 2 mM glutamine, 1 % nonessential amino acids, 100 U/ml streptomycin, 100 U/ml peni-
cillin, and 7 .5% FCS.
Virological Techniques.
￿
Viral stocks were isolated from NIH/3T3 cells infected with 4070A
amphotropic murine leukemia virus (MuLV) (24), or from nonproducer NIH/3T3 cells, con-
taining either viral Kirsten-ras (Ki-ras) or Harvey-ras (Ha-ras) gene sequences, superinfected
with 4070A amphotropic helper MuLV (26). Viral pseudotypes were collected as fresh 24-h
cell-free supernatant fluids and frozen at -70°C until use. Approximately 4 x 105 PT cells
(passage 1) were pretreated for 60 min with DEAF/dextran (25 ltg/ml), washed, then incubated
with virus at a multiplicity of infection of 1 focus forming unit/cell. Transforming activity
of amphotropic pseudotype virus produced by infected cells was determined by focus assays
on NIH/3T3 cells. Nonpseudotype virus production by PT cells infected with the amphotropic
parent 4070A-MuLV was quantitated by titrating cell supernatants on NIH/3T3 cells and
determining the expression of the core p30 gag gene protein in the cytoplasm as described
(24). The ability of viral-infected cells to form growing colonies in soft-agar (27) and infec-
tious centers on NIH/3T3 cells (28) was determined as described (24).
Serological Reagents.
￿
The specificity of mouse mAbs to human antigens is as follows: S4/URO-
2 : recognizes a glycoprotein (gp) of 160 kD, gp160, on the glomerulus and PT portion of
the nephron (13); T43/URO-10: recognizes a gp of85 kD (gp85) on the PT (29); F23/URO-3:
recognizes a gp of 140 kD (gp140) on the PT (15); S27/URO-4, S23/URO-4a and S6 : recog-
nize different epitopes of the adenosine deaminase binding protein, a gp of 120 kD (gpl20)
on the PT and the loop ofhenle (LH) (16); AJ8: recognizes the common acute lymphoblastic
leukemia antigen (CALLA; a gp of 100 kD) on the glomerulus and PT (30); F31/URO-8:
recognizes a lipid on the PT cell (16); 10.32: recognizes the Tamm-Horsfall protein, a gp
of 90 kD (gp90) on the LH and DT [14] ; CAM 5.2 : recognizes cytokeratin polypeptides with
molecular weights of 40, 45, and 52 kD, found in epithelial cells (31); P12 (SSEA-1): recog-
nizes the Lewis X blood group antigen on the PT (17, 32); R24: recognizes GD3 ganglio-
side (33); 3F8: recognizes GD2 ganglioside (34); and BDID2C3: recognizes villin (35). Non-
mouse antibodies used were rat mAB Y13-259 (36), which reacts with the 21-kD (p21) protein
encoded by the viral Ha or Ki-ras, and polyclonal rabbit anti-Rauscher-MuLV group-specific
p30 serum (37).
Immunoperoxidase Staining.
￿
Immunoperoxidase staining ofantigens was performed as pre-
viously described (31) . Briefly, cells were seeded into LabTek tissue culture chamber/slides
(Miles Scientific, Naperville, IL) and incubated at 37°C in a C02 chamber for 24-48 h. The
slides were fixed with methanol at -20°C for 10 min, quenched for 15 min in 1% hydrogen
peroxide in PBS, washed several times with PBS, and incubated with suppressor serum (10%
normal horse serum; Cappel Laboratories, Cochranville, PA) for 20 min. The suppressor
serum was removed and sections of cells on each slide were incubated with appropriately
diluted primary antibody overnight at 4 °C. The avidin-biotin method used a biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA) as described (38). 5 mg of di-
aminobenzidine (DAB) tetrahydrochloride in 100 ml of PBS with 100 i1 of 0.3% hydrogen
peroxide was used as chromogen. The DAB solution was filtered and incubated with the slides
for 5-10 min. After treatment, slides were washed with distilled H2O, counterstained withNANUS ET AL.
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hematoxylin, and mounted with Permount (Fisher Scientific, Fair Lawn, NJ). Slides were
examined with an epifluorescent microscope and reactivity was graded from 0 to 3 + by two
independent observers.
Immunofluorescence Assay.
￿
Detection of villin with BDID2-C3 antibody was performed as
previously described (35). Briefly, cells were allowed to replicate on LabTek slides as described
above, fixed on the culture slide with periodate-lysine-formaldehyde, and labeled with
BDID2-C3 antibody (in 0.1 M sodium cacodylate, pH 7.4). The sections were incubated with
rabbit anti-mouse IgG secondary antibody conjugatedto fluorescein (Cappel Laboratories)
diluted at 1 :1,000, and examined with a microscope equipped with epifluorescence and a
100-W mercury lamp. Reactivity was graded from 0 to 3+ by two independent observers.
SerologicalAssays.
￿
The protein A and anti-mouse Ig hemadsorption assays were performed
as described (24). Indicator cells were prepared by conjugating either protein A (Pharmacia
Fine Chemicals, Piscataway, NJ) or the Ig fraction of rabbit anti-mouse heavy chain (Dako
Corp., SantaBarbara, CA) to human 0 + erythrocytes with 0.01 0 /0 chromium chloride. Assays
were performed in microtest plates (model 3040; Falcon Labware, Oxnard, CA). Target cells
(plated 1-2 d previously) and serial antibody dilution were incubated for 1 h at room temper-
ature. Target cells were then washed and indicator cellswere added for 45 min. Target cells
were washed again to remove nonadherent indicator cells. Titers were defined as the anti-
body dilution showing 20% positive (rosetted) target cells as evaluated under lightmicroscopy.
Immunoprecipitation Analysis.
￿
Cells (in a near confluent 150-cm2 flask) were radiolabeled
by metabolic incorporation of ["S]methionine (1,000 Ci/mmol; New England Nuclear,
Boston, MA) using 500 ltCi in 10 ml of methionine-free MEM containing 7 .5% dialyzed
FCS for 16 h. Labeled cells were extracted as described (39). 0.05 ml of protein A-agarose
beads (Boehringer Mannheim Biochemicals, Indianaopolis, IN) were incubated with 0.02
ml of goat anti-rat Ig (Dako Corp.) and 0.08 ml of complete buffer (CB: 10 mM Tris-HCI,
pH 7.2, 150 mM NaCl, 0 .5% NP-40, 0.1% SDS) for l h with rotation at VC, and washed
five times with CB. The beads were resuspended in 0.05 ml CB and incubated with 5 ul of
undiluted ascites fluid Y13-259 (anti-p21) for 1 h at 4°C, then washed five times with CB.
Immunoprecipitation was carried out by incubating a portion of the cell extract (107 cpm)
with the beads and CB to a total volume of 0.3 ml for 16 h at 40C . The beads were washed
six times with CB and four times with CB/high salt (2.1 gm NaCl in 100 ml CB) . Labeled
components were detected by SDS-PAGE and fluorography as described (39).
Radiolabeled BindingAssayfor Gangliosides.
￿
Cells were trypsinized and resuspended in Tris-
MEM (490 ml unsupplemented MEM, 10 ml 1 M Tris, pH 8.0, 2 gm BSA, 40 mg sodium
azide) at a concentration of 1-2 x 106 cells/ml. 96-well plates (Dynatech Laboratories, Alex-
andria, VA) were preincubated with Tris-MEM (0.1 ml/well) for 30 min at room tempera-
ture. The media was discarded and the wells were allowed to air-dry. A cell suspension of
5 x 104 to 1 x 105 cells/0.05 ml Tris-MEM was deposited in each well, together with 0.05
ml ofantibody diluted serially, and incubated for 1 h at 4°C. All incubations were performed
in triplicate. After the incubation, the plates were centrifuged at 1,200 rpm for 5 min and
washed three times with Tris-MEM. Cells were resuspended in 0 .05 ml Tris-MEM together
with 100,000 cpm of '251-labeled protein A (in 0.05 ml Tris-MEM) for 1 h at 4°C, washed
five times, and allowed to air-dry overnight at 37°C. Individual wells were placed in Omni
plastic vialsand quantitated in a gamma counter (Packard Instrument Co., Downers Grove, IL).
Thin-Layer Chromatography. Cells were radiolabeled by metabolic incorporation of
[3H]glucosamine (New England Nuclear) 30-60 Ci/mmol, by using 500 pCi in 10 ml of
MEM with 10% FCS for 72 h. Radiolabeled cells were extracted successively with chloro-
form/methanol 2 :1, 1 :1, and 1 :2 and the acidic glycolipids were isolated by florosil and DEAD-
sephadex chromatography as described (40). Radiolabeled gangliosides were separated by
thin layer chromatography in chloroform/methanol/2.5-N-ammonium hydroxide (60 :35:8)
and detected by spraying the plate with Enlightening (New England Nuclear), air-drying,
and exposing to XAR5 film (Eastman Kodak Co., Rochester, NY).
Growth Factor Analysis.
￿
Conditioned serum-free medium (CM) was collected from 90%
confluent monolayers of cells growing in 150-cm2 flasks after 72 h, dialyzed in acetic acid,
lyophilized, and reconstituted in logo BSA/PBS as described (41, 42). The concentration of
protein in each sample was determined using a colorimetric protein assay (Bio-Rad Labora-956 VIRAL Ki-ras OR Ha-ras ONCOGENES IN RENAL PROXIMAL TUBULE CELLS
tories, Richmond, CA). Other reagents include epidermal growth factor (EGF) (culture-grade;
Collaborative Research, Inc., Bedford, MA) and transforming growth factora (TGR0) (gener-
ously provided by M. B. Sporn, National Institute of Health, Bethesda, MD). NRK cells,
clone 49F (American Type Culture Collection, Rockville, MD), were grown in MEM as de-
scribed above. Soft-agar colony-forming activity was determined using NRK clone 49F cells
grown in 0.35% agar in the presence or absence of added growth factors, CM, or both (41,
42). The number and size of colonies were determined at day 14 by counting microscopic
fields using a grid.
CytogeneticAnalysis.
￿
Karyotypic analysis was performed as previously described (43). Briefly,
mitotic cells were arrested by exposure to colcemid (0.05 /4g/ml) for 2 h at 37°C before har-
vesting. Cell suspensions were treated with a hypotonic solution (0.075 M KCl) for 20 min
at 37°C, fixed with Carnoy's fixative (methanol/acetic acid, 3 :1), and washed three to five
times. Air-dried slides were stained with quinacrine mustard. 30-50 metaphases were pho-
tographed, counted, and analyzed; 12-20 metaphases were karyotyped. Chromosome identi-
fication followed the International System for Human Cytogenetics Nomenclature (ISCN) (44).
IFN Binding to Cells.
￿
Recombinant DNA-derived IFN-a Con1, designed as a consensus
of the known IFN-a subtypes (Amgen, Inc., Thousand Oaks, CA) (45) was coupled to 1211
by using limiting amounts ofchloramine T Iodinated IFN-ca (-150 Ci/gm), separated from
free "'I on a column of G-50 Sephadex, retained >90% of its antiproliferative and antiviral
activity on sensitive cell lines (46). For analysis of '251-IFN-a binding to cells, monolayer
cell lines were washed with PBS, and harvested by incubation with 1 mM EDTA in PBS for
5 min at 37°C. Cells were resuspended at 2 x 106 cells/ml in Dulbeccds modified Eagle's
MEM supplemented with 10 ° Io FCS and containing 20 mM Hepes and incubated with varying
concentrations of 1251-IFN-a (1-100 pM). After incubation for 100 min at 15°C, duplicate
200-Al aliquots ofthe binding mixture were layered over 150 p,l of a mixture ofdi-n-butyl/dinonyl
phthalate (2:1) in a 400-11 microcentrifuge tube and centrifuged (10,000 g, 1 min). The su-
pernatant medium was aspirated, the top of the tube was aspirated with 200 pl of distilled
water, and the oil was aspirated in the final rinse. The tip of each tube was cut off, and the
cell-bound radioactivity was assayed in a gamma counter. The specific binding of '25I-IFN-a
is determined by the difference of ' 25I-IFN binding in the absence and presence of 10 nM
unlabeled IFN-a. Data are plotted according to the procedure of Scatchard (47) and ana-
lyzed by a linear nonreiterative least square curve fitting program.
IFN Effect on Proliferation.
￿
Cell lines were plated at 105 cells/25-cm2 flask in Dulbeccds
MEM. After 1 d the cells were refed with medium containing IFN-a at varying concentra-
tions (100-3,000 U/ml). Control cultures received no IFN . At 6 d after IFN-a addition, cells
were washed once with PBS and harvested by trypsinization for 5 min at 37°C. Cell counts
were performed on a Coulter counter (Coulter Electronics, Hialeah, FL). The ratios of the
cell number on day 6 to that on day 0 in IFN-treated cultures were expressed as a percentage
of the ratio in untreated control cultures.
Results
Biological Characteristics.
￿
2 wk after infection of passage 1 kidney cultures with
amphotropic retroviruses containing either the Kirsten-ras (Ki-ras) or the Harvey-
ras (Ha-ras) oncogenes, islands of rapidly proliferating cells appeared possessing mor-
phologies similar to those seen in renal cancers. Cultured renal cancers display three
main morphological types (10) : (a) well-defined spindle shaped cells that grow in
mounds several layers deep; (b) islands of compact epithelial cells with irregular, sharply
defined edges; and (c) globular shaped cells with pseudopod-like structures. In con-
trast, cultured normal kidney cells demonstrate either crescentic, round or polyg-
onal configurations (48). Ki-ras-infected cells (termed PTKi) appeared similar to
type 1 renal cancers that have a well-defined spindle shaped morphology. Ha-ras-in-
fected cells (termed PT Ha) grew as islands of compact epithelial cells similar to type
2 renal cancer cells. Sister kidney cultures infected with control 4070A amphotropic0 100
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0
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MuLU, whichdoes notcontain an oncogene, maintained acharacteristically normal
morphology.
Infected PTKi and PTHa cellsproliferatedvigorouslybeyond passage 3, becoming
the dominant cell in theculture by 4 wk after infection. Fig. 1 compares the growth
potential ofPT-Haand PTKi cells with uninfected kidney cells and 4070A-infected
cells. The increased proliferative capacity of PTKi and PTHa cells, sustained in
culture for>24 mo, is in sharp contrast tonormal kidney cells, which, though capable
ofrapid growth between passages 0-2, manifest a sharp decline in growth rate after
passage 2 and senesce by passage 4 or 5 (i.e., by 8-10 generations) (10).
Uninfected kidney cells exhibit other biological traits characteristic ofshort-term
cultures ofnormal cells, includingcontact inhibition andanchorage-dependent growth.
In contrast, renal cancer cells can replicate indefinitely in culture, do not exhibit
contact inhibition, and form colonies in semi-solid medium with high efficiencies
(10; Bander, N. H., unpublished results). Table I compares the biological character-
istics ofearly passage (i.e., <17 passages) PTKi and PTHa cells with those ofrenal
cancers and early passage normal kidney cells. Similar to renal cancer cells, PT-Ha
and PTKi cells (a) are apparently immortalized as they do not senesce by passage
5 (as do normal kidney cells) and have an unlimited growth capacity, (b) are not
contact inhibited, growing to high saturation densities and in multiple cell layers,
TABLE I
Biologic Characteristics of Cultured PT Cells
FIGURE 1.
￿
Growth kinetics of PT cells. Growth
rates ofPTKi cells at passage 12 (O); PTHacells
at passage 6 (A); PT cells infected with 4070A-
MuLU at passage 3 (*); and uninfected PT cells
at passage 3 (0).
+, presence of phenotypic trait; -, absence of phenotypic trait.
' Defined as the ability to proliferate beyond passage 5 and to be subcultured at a low-seeding
density (i.e., <100 cells/cm2).
Growth factor production determined by NRK colony forming assay.
§ Defined as having an immortalized phenotype.
II Defined as the ability to form colonies in semi-solid media.
Biological
trait
Normal
kidney
PT-Ki
cells
PT-Ha
cells
Renal
cancers
Proliferative capacity' - + + +
Contact inhibition + - - -
Growth factor production) _ + + +
Unlimited growths - + + +
Anchorage independencell - - - +
Karyotype Diploid Aneuploid Aneuploid Aneuploid958
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(c) produce growth factors (see below), and (d) have an aneuploid karyotype (see
below) . One notable dissimilarity is that, during early passages, PTKi and PTHa
cells are still anchorage dependent . At later passages, however (see below), PTKi
cells acquire the capacity for anchorage-independent growth in soft agar with a high
efficiency. Kidney cells infected with control 4070A virus maintained all the pheno-
typic characteristics of uninfected normal kidney, manifesting a decline in growth
rate at passage 3 and senescing by passage 5 .
Virological Characteristics.
￿
Infectious center analysis at passage 5 indicated that 100%
ofPTKi and PT-Ha cells were infected and releasing transforming virus particles .
Supernatants from PTKi and PTHa cultures contained between 10 3 and 105 in-
fectious virus particles per milliliter. A Northern blot analysis demonstrated the pres-
ence of messengerRNA transcripts of either Ki-ras or Ha-ras oncogenes in Ki- or
Ha-infected cells respectively (not shown) . The presence of viral ras-encoded p21
protein in PTKI and PT-Ha cells was confirmed by immunoprecipitation studies
(see Fig . 2) and Western blotting (not shown). Control MuLUinfected kidney cul-
tures assayed for cytoplasmic viral p30 gag gene protein showed that 100% of the
cells were infected .
Proximal Tubule Cell Origin of Infected Kidney Cells.
￿
90% of the cells in passage 0
normal kidney cultures are derived from the PT portion of the nephron and are
ofepithelial origin (10-12, 48) . The remaining 10% of cultured cells originate either
from other divisions within the nephron (i .e ., glomerulus, distal tubule, or collecting
duct) or from connective tissue. The precise derivation ofPT Ki and PTHa cells
was defined by determining the expression of a series of cell surface and cytoplasmic
kidney cell markers . First, as summarized in Table 11, PTKi and PTHa cells strongly
immunostained for low molecular weight cytokeratins, confirming an epithelial origin
(31) . Second, PTKi and PTHa cells expressed villin, a95-kD molecular mass pro-
tein found only in intestinal epithelium and renal proximal tubule epithelium (49,
50) . Third, as determined by immunorosetting assays, PTKi and PT-Ha cells ex-
pressed a number of surface antigens characteristic ofthe PT portion of the human
nephron . These antigens include (a) adenosine deaminase binding protein (ADA
bp) [16] ; (b) cell surface glycoproteins recognized by mAbs S4/URO-2, F23/URO-
3, and T43/URO-10 (13, 15, 29) ; (c) the CALLA recognized by mAb AJ8 (which
is also expressed by lymphocytes) (16, 30) ; and (d) the LewisX blood group antigen,
a carbohydrate structure found on the PT portion of the nephron (17), as well as
FIGURE 2 .
￿
Immunoprecipitation of ras p21 protein. Autoradiograms of im-
munoprecipitates obtained with mAb Y13-259 (anti-p21) and extracts of
[ 35S]methionine-labeled PT-Ha and PTKi cells as analyzed by SDS-PAGE .
(Lane 1) PT-Ha cells ; (lane 2) PTKi cells : (lane 3) uninfected normal PT cells .
Arrow shows p21 protein .NANUS ET AL.
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TABLE II
PT Phenotype of Infected Kidney Cells
Cultured kidney
￿
PT-Ki
￿
PT-Ha
cells
￿
cells
￿
cells
Expression of adenosine deaminase binding protein (ADAbp), and the anti-
gens S4/URO-2, F23/URO-3, T43/URO-10, and AJ8 (CALLA), the Lewis
X blood group antigen (Le', SSEA-1), and the Tamm-Horsfall protein was
determined by erythrocyte rosetting assays. Values represent reciprocal ofse-
rum titers x 10 1, at which 20% of the cells were positive. (-) Indicates no
positive cells.
* Keratin expression determined by immunoperoxidase staining and scored 0
to 3 +
I Villin expression was determined using immunofluorescence staining and scored
0 to 3+ .
on the surface of erythrocytes and various epithelia of the body (51). The Tamm-
Horsfall protein, expressed by the distal tubule portion of the nephron (16), was not
expressed by PTKi, PT Ha, or normal kidney cells. Based on the pattern of antigen
expression, infected PTKi and PT-Ha kidney cells were judged to be of PT origin,
and not of glomerular, distal tubule, collecting duct, or connective tissue origin. In
addition, there were no qualitative changes in the expression ofany ofthese antigens.
Antigenic Alterations in Infected PT Cells.
￿
In contrast to the series of antigens dis-
cussed above, cultured renal carcinomas express antigenic determinants apparently
related to the transformation process. Two of these determinants are the disialogan-
gliosides GD2 and GD3, each of which is expressed by a distinct subset of renal
cancers but not by normal kidney (Albino, A. P., unpublished results). GD3 could
be detected on the cell surfaces of PTKi and PT-Ha cells at the earliest time point
analyzed (i.e., 2 wk after infection) with immunorosetting assays (see Table III).
The induction of GD3 expression in these cells was confirmed by direct isolation
and analysis on thin-layer chromatography (TLC) (Fig. 3). Radiolabeled binding
studies indicated that the quantity of GD3 in PTKi and PT-Ha cells increased 5-10-
fold as compared with uninfected PT cells or PT cells infected with control 4070A
virus. GD2, whose structural precursor is GD3 (52), was not detectable in either
PTKi or PTHa cells at early passages (i .e., <17). However, by later passages (i.e.,
24), GD2 could be detected in PTKi cells by direct binding of radiolabeled anti-
GD2 antibody, but not by the less sensitive TLC method. PT-Ha cells did not ex-
press detectable levels of GD2 even at similarly late passages. We noted (and fur-
ther discuss below) that the expression of GD2 in PTKi cells appeared concurrently
with the acquisition of an anchorage independent phenotype. PT-Ha cells also did
not convert to an anchorage-independent mode of growth. In contrast to GD3 and
Keratins*
Villinl
3 +
1 +
3 +
1 +
3 +
1 +
ADAbp 10,000 1,000 1,000
S4/URO-2 100 100 10
F23/URO-3 100 1,000 1,000
,r43/URO-10 100,000 100,000 100,000
AJ8 (CALLA) 1,000 100 100
Lc' (SSEA-1) 100 100 1,000
Tamm-Horsfall protein - - -960
￿
VIRAL Ki-ras OR Ha-ras ONCOGENES IN RENAL PROXIMAL TUBULE CELLS
TABLE III
Lipid Content of Normal and Transformed Kidney Cells
Ganglioside content was determined by immunorosetting and/or TLC . + ,
antigen expressed ; - , antigen not expressed .
' Increased expression of GD3 ganglioside is present in 10% of renal cancers
(see text) .
F31/URO-8 is a lipid expressed by over 70% of renal cancers .
3 Cells from the convoluted PT .
GD2, expression ofGM3 ganglioside in PTKi and PTHa cells appeared to be un-
altered .
A third transformation-related antigen that is differentially expressed by kidney
cancers and normal kidney cells is an undefined lipid recognized bymAb F31/URO-8 .
This lipid moiety is expressed on the cell surfaces of 70% of cultured renal cancers
(16, 21), but undetectable on cultured cells derived from the convoluted proximal
tubule (see Table III) . The F31/URO-8 antigenwas undetectable on the cell surfaces
of PTKi or PT-Ha cells .
Growth Factor Production .
￿
A fraction of cultured and noncultured renal cancers
produce growth regulatory factors collectively referred to as transforming growth
factors (TGFs) (53, 54 ; Nanus, D.M ., unpublished results) . To determine whether
transformed PTKi or PT-Ha cells generate TGFs,CM derivedfrom these cellswere
tested in the NRK soft-agar growth assay . TGFs induce normal rat kidney (NRK)
fibroblasts to form colonies in soft-agar, thereby providing an assay to detect and
quantitate the mitogenic activity of these factors (42) . Furthermore, combinations
of variousgrowth factors apparently act synergistically, causing the number and size
ofNRK colonies to increase (42, 55) . As summarized in Table IV, CM from PT-Ha,
PTKi (early and late passages), and 1/3 renal cancers cell lines induced colony-
formation of NRK cells in soft agar, thereby indicating the presence of TGFs in
the supernatants . TableV shows that theCM from passage 24 PTKi cells induced
the formation of large colonies (>100 /,m) in either the absence or presence of up
to 100 ng of EGF per milliliter. This latter result indicates that theCM from these
cells contained more than one biologically distinct growth factor, the precise bio-
chemical nature of which remains to be elucidated .
FIGURE 3 .
￿
Analysis of gangliosides by TLC . (Lanes 1 and 2) Two inde-
pendent uninfected PT cell cultures; (lane 3) PTKi cells ; (lane 4)PTHa
cells . Marker lane shows migration of purified gangliosides .
Normal PT
cells
PT-Ki
cells
PT-Ha
cells
Renal
carcinomas
GM3 ganglioside + + + +
GD3 ganglioside - + + 10%*
GD2 ganglioside - - - 10%
F31/URO-81 -3 - - 70%NANUS ET AL.
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TABLE IV
Transforming Growth Factor Activity in Renal Cell Lines
Source of
￿
Number of NRK-49F
conditioned media'
￿
colonies$
Normal kidney 1
￿
<2
Normal kidney 2
￿
<2
SK-RC-21
￿
<2
SK-RC-46
￿
<2
SK-RC-42
￿
61
PT-Ha (early passage)
￿
1505
PT-Ki (early passage)
￿
1305
PT-Ki (late passage)
￿
1255
1, 700 gg ofprotein from processed conditioned media was added to each well.
$ 3 x 103 cells were seeded in soft agar as described in Materials and Methods.
Colonies were allowed to form for 14 d. Values represent the mean of dupli-
cate plates.
5 Colony size >100 Wm; all others have a colony size <100 um,
Karyotypic Analysis ofPT Cells,
￿
Cytogenetic analysis of a short-term culture of
uninfected PT cells indicates a normal diploid male karyotype (46, XY). In con-
trast, cytogenetic analyses of PTHa cells (passage 3) and PTKi cells (passage 4)
demonstrated nonrandom abnormalities involving chromosome21 in bothlines. Fig.
4 shows that the karyotypic anomaly in PTKi cells was a translocation between the
q portions ofchromosomes 1 and 21, specifically der(21)t(1;21) (g21;q22), which was
observed in 92.5% of cells analyzed (see Table VI). Fig. 5 shows that PT-Ha cells
were monosomic for chromosome 21, an abnormality which was observed in 50%
of cells analyzed (see Table VI).
Progression ofInfectedPTCells.
￿
Serially passaged PTKi and PTHa cellswere reg-
TABLE V
Transforming Growth Factor Activity in Conditioned Mediumfrom PT-Ki Late Passage Cells
' 3 x 103 cells were seeded in soft agar as described in Materials and Methods. Colonies were
allowed to form for 14 d. Values represent the mean number ofcolonies from duplicate plates.
$ 1,700 FAg of protein from processed conditioned media was added to each well.
5 Colony size >100 um ; all others have a colony size <100 pm.
Growth factor
added Amount
ng/ml
Number of
Growth factors minus
conditioned medial
NRK-49F colonies
Growth factors plus
conditioned media:
None <2 385
EGF 0.05 <2 305
EGF 0 .5 <2 725
EGF 5.0 25 1905
EGF 10 .0 26 1385
EGF 100.0 22 1335
TGF-O 0.5 <2 965
EGF plus 5 .0 1335 ND
TGF-l3 0.5962
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FIGURE 4 .
￿
Q-banded karyotype ofPTHa cells . Arrow indicates loss ofone copy ofchromosome
21 (45,XY,-21) .
ularly monitored to identify temporal and progressive alterations in their antigenic,
biologic, and chromosomal phenotypes . A comparison of the biological and anti-
genic phenotypes of early passage (i.e ., <17) PT-K1 and PT-Ha cells indicated that
these cells possessed all of the measured characteristics ofPT cells and renal cancers
with the exception of anchorage independence .
We noted that by passage 24 (N8 mo in culture), PT K1 cells spontaneously ac-
quired an anchorage-independent phenotype, and could form colonies in soft agar
TABLE VI
Chromosomal Rearrangements in PT-Ki and PT-Ha Cells
Stem line (sl) refers to the most frequent karyotypes (with respect to chromosome number and/or
chromosome structure) of a tumor cell population .
Cell
line
Cell
passage
Stem
line Karyotypic deviations
Percent of cells
with der(21)
PT-Ki 3 sl 46,XY,-21,+dcr(21)t(1 ;21)(g21 ;q22) 92 .5
PT-Ki 24 sl 46,XY,-21,+dcr(21)t(1 ;21)(g21 ;q22) too
PT-Ki 57 sl 47,XY,-3,-21,+20,+dcr(3)t(3 ;?)(q27 : :?) 10o
+dcr(21)t(1 ;21)(g21 ;g22)
Percent of cells
with monosomy 21
PT-Ha 3 sl 45,XY, - 21 50
P'1'-Ha 24 45,XY, - 21 14 .2NANUS ET AL .
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FIGURE 5 .
￿
Q-banded karyotype ofPTKi cells . Arrow shows loss ofchromosome 21 and boxed
figure indicates the involvement of chromosome 21 in conjunction with chromosome 1 (46,XY,
-21,+der(21)t(1;21)(g21;q22) .
with an efficiency of -10% . Karyotypic analysis of these cells revealed that 100%
of the cells still displayed der(21)t(1;21)(g21;q22) observed in early passage cultures ;
but, in addition, other secondary chromosomal abnormalities were observed . Since
the acquisition of anchorage independence occurred as a relatively discrete tem-
poral event, we attempted to correlate the development of this phenotype with a
specific secondary chromosomal abnormality. PTKi passage 24 cells were cloned
in soft agarand five individual clones were isolated, grown to mass culture and their
karyotypes analyzed (Table VII, reference 56) . Aside from the der(21)t(1;21)(g21;q22),
which persisted in 100% of the cells from each ofthe 5 clones, no common secondary
chromosomal abnormality (which included numerical and structural alterations in
TABLE VII
Chromosomal Deviations in Soft-agar Clones of PT-Ki Cells
Stem line (sl) refers to the most frequent karyotypes (with respect to chromosome number and/or
chromosome structure) of a tumor cell population .
Cell
line
Stem
line Karyotypic deviations
Percent of cells
with der(21)
Clone 1 sl 45,Y,dic(X;15)(gter-pier),-21,dup(7) 100
(g21 ;q31), + der(21)t(1 ;21)(g21 ;q22)
Clone 2 sl 45,X,-Y, -21 +der(21)t(1 ;21)(g21 ;q22) 100
Clone 3 sl 46,XY,-21,19q+,+der(21)t(1 ;21)(g21 ;q22) 100
Clone 4 sl 46,XY,-21,18p+,+der(21)t(1 ;21)(g21 ;q22) 100
Clone 5 sl 44,X,-Y,-18,-21,19q+,+der(21)t(1 ;21)(g21 ;q22) 100964
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chromosomes [l, 5, 7, 8, 15, 18, 19, X and Y; and see reference 56] appeared to
correlate with the acquisition ofanchorage independence. The five soft agar clones
and the parental PTKi cells were analyzed for other progressive alterations. Each
ofthe clones and the parental cells continued to express a proximal tubule pheno-
type as well as GD3 ganglioside. But, in addition, each of these cell lines also ex-
pressed GD2 ganglioside (whose biosynthetic precursor is GD3), as detected by di-
rect serological and binding assays. Most interesting, however, was the observation
that upon further subculturing and subsequent chromosomal analysis (i.e., at pas-
sage 57), PTKicells manifested, inaddition toder(21)t(1;21) (g21;q22), a rearrange-
ment ofchromosome 3 and an additional copy of chromosome 20 in 100% of the
cells. Chromosome 3 has been implicated as having afundamental role in thepatho-
genesis of renal carcinoma and it is postulated that a recessive oncogene is present
on the short arm (57, 58).
Analysis ofPT-Hacells at passage24 revealed no new antigenicor biologic altera-
tions. Chromosomal analyses of these cells at passage 24 showed that monosomy
21 persisted in 14.2% of cells (Table VI).
Analysis of Genes on Chromosome 21.
￿
To date, 17 genes have been assigned to chro-
mosome 21, including the proto-oncogenes ets2, beel, and erg, and the gene coding
forthe receptors fortypeI interferons (a anda) (59, 60). We have begun an analysis
designed to detect the presence of abnormalities in these genes. First, high molec-
ular weight DNA from PTKi, PT-Ha, and renal cancer cell lines was analyzed by
Southern blotting for the presence of rearrangements in the ets2 gene. Compared
with normal diploid proximal tubule cells, each ofthe cell lines tested had anormal
genomic organization ofthe ets2 gene, indicatingnorearrangementor amplification
in the regions comprising this gene (data not shown).
Second, alterations in typeIinterferon (IFN-a)receptors were analyzed bydeter-
mining thereceptor number and the affinityofthese receptorsforinterferon. Binding
data obtained at 15°C were plottedaccording tothe method ofScatchard (47), which
yielded linear plots. Both PTKi and PT-Ha cell lines possess similar numbers of
high affinity IFN-alpha binding sites (Kd '100 pM; 1,500 and 1,250 receptors/cell
for PTKiandPT-Ha, respectively). These numbers ofIFN-ca receptorsandthe affinity
of IFN-a binding are comparable to values obtained with several cell types, both
malignant and normal (Pfeffer, L. M., unpublished results). We have found that
a subset ofcultured renal cancers are sensitive to the antiproliferative action of IFN
(Nanus, D. M., et al., unpublished results), and thus, analyzed the sensitivity of
infected PT cells toIFN action. Both the PTKi and PTHa cell lineswere relatively
resistant to the antiproliferative action of IFN-a, with no significant inhibition ob-
served at IFN concentrations below 15 pM. At 150 pM IFN, there was only 40%
inhibition ofcell proliferation, asdetermined by the fold-increase in the treated cul-
ture relative tothat inuntreated control cells. The level ofinhibition ofcell prolifera-
tion in the transformed cell lines is similarto the inhibition that has been observed
in several lines ofnormal human kidney cells andin diploidhuman fibroblasts (Pfeffer,
L. M., N. H. Bander, and A. P. Albino, unpublished results).
Discussion
Ourobjectivewasto define thebiologic, antigenic, and geneticeffects ofintroducing
the Ki-ras or Ha-ras oncogenes into normal humanPTcells, the normal cellular coun-NANUS ET AL.
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terpart ofrenal cell carcinomas. Our goal is to use PT cells(a) as a model oftransfor-
mation, ascertainingthe temporal sequenceofevents involved inthe etiology ofrenal
carcinoma, and (b) as a system fordefining the relationship ofthese events with the
presence of specific oncogenes. We report there that the introduction of the Ki-ras
or Ha-ras oncogenes initiates a complex series ofevents which propels the PT cell
towards transformation in a temporal sequence, resultingin cells resemblingin vivo
renal carcinomas.
PT cells appear to undergo two distinct phases in response to infection with ras-
containing retroviruses. In thefirst or earlystage(i.e., between passages 1-3), ras-in-
fected PT cells manifest distinct morphological alterations and undergo a burst of
proliferation and outgrowth. Subsequently, these cells no longer senesce by passage
5, asdo normal PTcellsand PTcells infectedwith a non-oncogene-containing retro-
virus. In addition, ras-infected PT cells at this stage are not contact inhibited and
appear to be immortalized, in that theyare capable ofindefinite proliferation. How-
ever, these cells are still anchorage dependent.
Concomitant with the biologic alterations observed in the early phase, PT cells
containing a Ki-ras or Ha-ras oncogene also begin expressing GD3 ganglioside,
whereas untransformed PT cells do not. Induction ofGD3 expression occurredwithin
2 wk ofviral infection and correlated with the capacity ofPT cells to proliferate.
GD3 expression is apparently associated with the process ofmalignant transforma-
tion, as suggested by studies showing increased quantities of GD3 in (a) rat fibro-
blasts transfected with the adenovirus El transforming gene (61); (b) melanocytes
transformed in vitro (24) and in vivo (62), and (c) malignant glial cells (63). GD3
appears to be involved in both cellular adherence and membrane permeability (64),
and, furthermore, large concentrations may be necessaryfor sustaining ahigh meta-
bolic activity and/or rapid cellular proliferation (65).
IfGD3 has a fundamental role in the development ofthe transformed phenotype
in renal cancers, its precise effect appears to be complex; for even though ras-
transformed PT cells express high levels of GD3, our results show that only 10%
of renal cancers express detectable levels ofGD3. These results suggest several in-
terpretations, as follows: (a) GD3 is directly involved in the pathogenesis of most
renal cancers, but is only discernible, by the methods used, in a smallsubset oftrans-
formed renal cells; or (b) GD3 has a necessary role in only a minority of renal
cancers; or(c)qualitativealterations inGD3 expression may occur earlyin the trans-
formation process and are subsequently downregulated during progression; or (d)
GD3 is simply one ofmany glycolipid alterations to occur in transformed cells, and
whose sporadic appearance indicates a less important and more indirect role (52).
PTcells transformedwith rasoncogenesproduce atleast several, as yet undefined,
TGFs. Alterations inthemechanisms thatgovern endogenousgrowth factor production
inthesecells isa relatively rapid event, occurring early in thetransformation process
(i.e., by passage 17). The production ofgrowth factors by PT cells may be involved
in the transition from cells with alimited growth potential to cells possessing a dra-
matically increased proliferative capacity. Most renal carcinomas have an increased
expression of TGFa and -/3 in comparison to normal kidney (53, 54). Therefore,
while the preciseroleofTGFs in initiation or maintenance ofrenal cancers remains
to be determined, our results suggest that growth factor secretion and presumably
autocrine and/or paracrine growth stimulation may be a critical early event.966
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Perhaps the most crucial effect of the insertion of ras oncogenes into PT cells is
the resulting chromosomal instability, leading to the acquistion of advantageous genetic
alterations. Cultured PT cellshave a normal diploid karyotype, which is maintained
during the short life-span ofthesecells in culture. However, PT cells which undergo
outgrowth and alterations in proliferative capacity upon introduction ofras oncogenes
display consistent defects in chromosome 21. Early in the outgrowth phase PTKi
cells exhibit a specific 1 :21 translocation while PT-Ha cells lose an entire copy of
chromosome 21. It is unlikely that ras oncogenes are specifically causing these genetic
abnormalities as retroviral proviral genomms integrate in a generally random manner
(66); moreover, it is difficult to envision how a proviral genome could cause the specific
expulsion of an entire chromosome. Presumably, p21 protein triggers a cascade of
effects that affect a wide range of cellular functions, differentiation pathways, and
corresponding phenotypes. While our data do not suggest the precise nature of this
cascade on the normal management of genetic information, they do suggest that
a gene(s) or genetic element regulating (directly or indirectly) the proliferation of
PT cells may be present on chromosome 21, and that its disruption, by either trans-
location or deletion, provides a strong selective advantage, initiating or contributing
to the uncontrolled growth of these cells. We presume that this proliferation-related
gene resides at or near the site of translocation of chromosome 21 with chromosome
1 observed in PTKi cells. To identify this breakpoint we have begun an analysis
using polymorphic probes to specific portions ofchromosome 21. Of the genes identified
on this chromosome to date, we have analyzed the ets oncogene for gross rearrange-
ments and the type I interferon receptor for alterations in expression and binding
affinity, and have found no detectable perturbations in either of them.
In the second or late phase of PT cell transformation with ras oncogenes, PTKi
cells underwent detectable biologic and genetic progression, spontaneously acquiring
the capacity for anchorage-independent growth, and exhibiting additional chro-
mosomal alterations (Table VII). None ofthese secondary genetic abnormalities ap-
peared to correlate with the newly acquired anchorage independent phenotype, and
therefore, the precise genetic alterations governing anchorage independence may
not be detectableby karyotyping. Furthermore, despite the generation ofabnormal-
ities in otherchromosomes, the marker chromosome 21 defects were uniformly main-
tained in 100% of all cells examined, again indicating a strong selective advantage
of the genetic lesions involving chromosome 21.
The most common nonrandom chromosomal abnormalities reported in both familial
and nonfamilial renal carcinomas involve a translocation and/or deletion of the short
arm of chromosome 3, and/or trisomy or tetrasomy of chromosome 7 (57, 67). Less
frequent clonal chromosomal aberrations described, however, include trisomies 8
and 12, isochrome 1, loss ofsex chromosomes (67-69), and structural and numerical
aberrations of chromosome 21 (58, 68). Secondary chromosomal abnormalities in
late passage PTKi cells also involved chromosomes 1, 7, and 3 . The prevailing sup-
position is that genetic abnormalities on the short arm of chromosome 3 are pri-
marily responsible for the induction, maintenance, and metastases of renal cancers.
We suggest that chromosome 21 may have an early disruptiverole in at least a subset
ofrenal cancers that can be augmented or superceded by progressive genetic abnor-
malities involving chromosome 3. It is possible that defects in chromosome 3 in renalNANUS ET AL.
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cancers may be more responsible for the events inducing maintenance and metastases
rather than initiation.
Our results with PTHa cells are more difficult to interpret. 50% of early passage
cellshad monosomy 21, which is usually a lethal genotype (70). By passage 24, <15%
of these cells had this abnormality, yet the PT-Ha cells still maintained a transformed
phenotype. The simplest interpretation of these results is that either the karyotypi-
cally abnormal cellsare providing a growth stimulus, or, more likely, that the majority
ofcells with an apparent normal karyotype have one or more subchromosomal defects
(possibly on chromosome 21), which induces the cells to proliferate. Further analysis
of these cells may distinguish between these possibilities.
Normal diploid human cells have been difficult to transform with activated ras
oncogenes as the sole transforming agent (71, 72). However, in systems where cells
have either a genetically determined chromosomal abnormality, as in Bloom's syn-
drome (73), or have undergone extensive aneuploidy as a consequence of prolonged
passage in tissue culture (74), introduction of an activated ras oncogene can induce
the full range of transformation characteristics. While the precise complement of
ras oncogenes and host genes is unknown, these studies suggest that a combination
of an activated ras oncogene and aneuploidy may satisfy the minimal requirements
for transformation. A second effect of ras oncogenes appears to be a generalized in-
duction of chromosomal instability in diploid cells initiating a transformation cas-
cade leading to neoplastic transformation. Studies using normal human bronchial
epithelial cells transfected with a v-Ha-ras oncogene showed that after 3 mo of sub-
culturing, transformed foci ofimmortalized cells and neoplastic cells arose (74). Karyo-
type analyses of these cells at first passage after transformation revealed aneuploidy
with multiple chromosomal aberrations, but no specific, nonrandom chromosomal
changes. Specific genetic changes that contributed to the transformed phenotype
could not be deciphered. We have previously shown that the insertion of a ras on-
cogene into cultured human melanocytes results in a series ofmorphologic and anti-
genic alterations and a cellular phenotype characteristic of malignant melanoma
cells (24). Further, we have noted that an early response to ras oncogenes is the devel-
opment of hyperdiploid chromosome number; with prolonged passage and the gener-
ation of specific chromosomal abnormalities, these ras-containing melanocytes ac-
quired the fully transformed features ofmelanoma (Albino, A. P., unpublished data) .
Our studies with PT cells support the interpretation that Ki- and Ha-ras oncogenes
destabilize normal chromosomal structure by unknown mechanisms. If this insta-
bility results in biologically advantageous karyotypic abnormalities (and it is likely
that these will differ for each differentiated cell type), then the cell acquires altered
characteristics that release it from a normally disciplined and confined milieu. One
plausible consequence of this release can be increased proliferative capacity and a
potential for biologic and genetic progression driving the cell towards a transformed,
and ultimately, neoplastic phenotype. If this assumption is correct, it may be pos-
sible to define those complementing genetic lesions that may be directly or, more
likely, indirectly induced by the transforming and destabilizing potential of ras on-
cogenes.
In summary, it is clear that viral ras oncogenes have a pronounced effect on prox-
imal tubule cells, affecting alterations not only in morphology and antigen expres-968
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sion, but also in cellular mechanisms that appear to be necessary for progression
to a full malignant phenotype (e.g., anchorage independence and chromosomal in-
stability). Moreover, these alterations reflect events associated with renal carcinomas
and, more importantly, indicate a temporal association or sequence. What is the
evidence that activated ras genes are involved in the pathogenesis of renal cancers
in vivo? At present there is a lack of consistent ras perturbations in renal cancers.
Slamon et al. (75) reported a two to fourfold increase of Ha-ras m-RNA transcripts
in four and of Ki-ras transcripts in three ofseven renal carcinomas as compared with
autologous normal kidney. Others have also detected expression of c-Ha-ras, c-Ki-
ras, and N-ras in a limited number of renal carcinomas (76, 77). It is possible that
ras oncogenes are involved in the etiology of renal cancers but will require more sophisti-
cated approaches to discern; or that there are multiple pathways by which a PT cell
becomes neoplastic and there may exist a putative gene whose transforming poten-
tial is mimicked, or can be substituted for, by ras oncogenes; or that the products
of ras oncogenes and this unknown gene may intersect some common genetic ele-
ment which, if perturbed, could induce transformation-related events. In all proba-
bility, it is likely to be complex . If ras destabilizes normal chromosome structure,
and if this leads to the activation or deactivation of a proliferation related gene by
direct or indirect mechanisms, the stage may be set for the evolution of cells with
imprecise genetic instructions, ultimately acquiring a neoplastic phenotype.
Summary
Normal human kidney proximal tubule cells into which a ras oncogene was in-
serted undergo a series of transformation-related alterations that are characteristic
of renal carcinomas . These include changes in morphology, growth potential, an-
chorage dependence, antigen expression, growth factor production, and chromosomal
stability. Further, there are spontaneous progressive alterations in vitro in the karyotype
and antigenic profile of the transformed cells. Cytogenetic analyses suggest that al-
terations of chromosome 21 may play an early and pivotal role in the development
of transformed proximal tubule cells.
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